Delcath Systems Inc (DCTH.OQ)

DCTH.OQ on NASDAQ Stock Exchange Capital Market

0.41USD
11:05am EDT
Price Change (% chg)

$0.02 (+5.71%)
Prev Close
$0.39
Open
$0.39
Day's High
$0.41
Day's Low
$0.38
Volume
42,531
Avg. Vol
250,170
52-wk High
$2.37
52-wk Low
$0.35

DCTH.OQ

Chart for DCTH.OQ

About

Delcath Systems, Inc. (Delcath) is a development-stage, specialty pharmaceutical and medical device company, focused on oncology, initially cancers in the liver. Delcath focuses on the development and clinical study of the Delcath chemosaturation system. The Delcath chemosaturation system allows the administration of concentrate... (more)

Overall

Beta: 2.00
Market Cap (Mil.): $37.43
Shares Outstanding (Mil.): 96.73
Dividend: --
Yield (%): --

Financials

  DCTH.OQ Industry Sector
P/E (TTM): -- 27.50 37.76
EPS (TTM): -0.79 -- --
ROI: -179.51 9.26 18.76
ROE: -180.52 12.54 19.59
Search Stocks

REFILE-BRIEF-Delcath Systems to reduce its workforce in the United States by 20 percent

June 26 - Delcath Systems Inc : * Implemented a program to further reduce its workforce in the United States by 20% * Expects cash utilization for the fourth quarter of 2013 to be approximately $6 million to $8 million * Company's EU-based operations are not impacted by this realignment * Aim to cut expected cash burn in Q4 to approximately 50% of what it was in Q2 2012 * Source text for Eikon * Further company coverage

26 Jun 2013

FDA advisers recommend against Delcath's cancer therapy

- A panel of advisers to the U.S. health regulator unanimously recommended against approving Delcath Systems Inc's cancer therapy for a rare form of eye cancer that spreads to the liver, saying it was too risky.

02 May 2013

UPDATE 2-FDA advisers recommend against Delcath's cancer therapy

May 2 - A panel of advisers to the U.S. health regulator unanimously recommended against approving Delcath Systems Inc's cancer therapy for a rare form of eye cancer that spreads to the liver, saying it was too risky.

02 May 2013

FDA advisers vote against Delcath's cancer therapy

May 2 - A panel of advisers to the U.S. health regulator said that risks outweighed the benefits in Delcath Systems Inc's cancer therapy for a rare form of eye cancer that spreads to the liver.

02 May 2013

BRIEF-Delcath Systems shares down 6.2 pct premarket

NEW YORK, April 8 - Delcath Systems Inc : * Shares down 6.2 percent in premarket trading

08 Apr 2013

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: S&P Capital IQ Quantitative Report
$69.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00
Provider: Zacks Investment Research Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks